Effects of DHA in Patients With Multiple Sclerosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-31

Study Completion Date

2026-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial will investigate the effects of combining therapeutic exercise with DHA supplementation in 100 patients with multiple sclerosis using a randomized controlled design. Participants, diagnosed according to the McDonald criteria, will undergo functional, cognitive, fatigue, and quality-of-life assessments through tools such as the EDSS, BRB-N, MFIS, EVA-f, and MSQoL-54. Physiological evaluations will include infrared thermography, isokinetic strength testing, perceived exertion (Modified Borg Scale), balance (Timed Up and Go), lower-limb power (Sit-to-Stand app), and handgrip strength. The study hypothesizes that this combined intervention will improve motor function, cognition, fatigue management, and overall quality of life by enhancing neuromuscular activation and metabolic efficiency.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Natural Antioxidants in the Treatment of Multiple Sclerosis

NCT00010842

Multiple Sclerosis

COMPLETED PHASE1/PHASE2

Effects of Resistance Training in Multiple Sclerosis: a Randomized Trial.

NCT06478784

Multiple Sclerosis

RECRUITING NA

Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)

NCT01381354

Multiple Sclerosis

COMPLETED PHASE1

Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis

NCT00997438

Multiple Sclerosis

COMPLETED PHASE1

Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis

NCT02133664

Multiple Sclerosis Cognition

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Design

Randomized clinical trial.

Study Period

Two years: from January 2024 to January 2026.

Population Selection Reference Population

The study sample will be recruited from the Multiple Sclerosis Association (AMDEM) in the Region of Murcia and the Neurology Department of Hospital Ribera Salud in Molina de Segura.

Eligible participants will be patients diagnosed with multiple sclerosis (MS) according to the McDonald criteria, aged approximately 18 to 65 years, who have not experienced relapse episodes in the month prior to inclusion, and have an Expanded Disability Status Scale (EDSS) score between 0.0 and 6.0, as well as the ability to voluntarily activate the tibialis anterior muscle.

Sample Size

Given the characteristics of the study, the target sample size is at least 100 participants, divided into four groups (n ≈ 25 per group) according to treatment.

Participants will be randomly assigned to one of four groups, each following a different therapeutic protocol:

Group 1: therapeutic exercise protocol three times per week throughout the study + daily DHA supplementation (4 capsule/day).

Group 2: same exercise protocol + placebo capsule (sunflower oil) identical in appearance, color, and dosage.

Group 3: DHA supplementation only (4 capsule/day).

Group 4: placebo capsule only (sunflower oil), identical to intervention groups.

Statistical Design

A one-way or repeated-measures ANOVA will be used to test for statistically significant differences among three or more dependent samples.

Measurement time points will be defined as follows:

T0: baseline (pre-intervention).

T1: midpoint of the intervention (approximately 1.5 months after initiation).

T2: immediately after completing the 3-month intervention protocol.

T3: 3 months after the end of the intervention.

Data Collection Participant Characteristics

Sensitive data will be collected regarding:

Age, sex, height, weight, medication use, relapse episodes in the months prior to the study, disability status, disease condition, and cognitive function.

Additional psychophysical information will be gathered using validated questionnaires administered before and after the intervention:

Disability will be assessed using the Expanded Disability Status Scale (EDSS).

A score of 0.0 represents normal physical function without disability.

3-4 indicates mild impairment not limiting daily or work activities.

5-6 indicates moderate disability, typically able to walk but requiring assistance for about 100 meters at level 6.

7-9 represents severe impairment, often confined to a wheelchair or bed.

Cognitive function will be assessed using the Brief Repeatable Battery of Neuropsychological Tests (BRB-N), a validated tool for MS. It includes tests of selective recall, the 7/24 spatial recall test, the controlled oral word association test, and the paced auditory serial addition test (PASAT).

Fatigue will be measured using the Modified Fatigue Impact Scale (MFIS), assessing the perceived impact of fatigue on cognitive (10 items), physical (10 items), and psychosocial (20 items) functioning. Responses range from 0 (no problem) to 4 (extreme problem), with a maximum score of 160.

Quality of life will be measured with the Multiple Sclerosis Quality of Life-54 (MSQoL-54), a validated MS-specific scale that evaluates symptom severity, walking ability, absenteeism due to health, hospitalization history, depressive symptoms, and disease duration.

Functional Assessments

Pre, during and post--intervention.

Infrared thermography will capture whole-body thermal images before, during, and after the intervention as a non-invasive, reliable, and cost-effective diagnostic tool. Measurements will be taken:

Pre and post--intervention.

The Modified Borg Scale will be used to adjust exercise load intensity, maintaining perceived exertion between 5-7. If the score falls below 5, resistance will be increased by adding up to 5 kg. This will be recorded in the final session of each week.

The EVA-f scale (adapted fatigue visual analogue scale) will be used to measure subjective fatigue perception (0 = no fatigue; 10 = extreme fatigue) at the end of each training session.

The Sit-to-Stand App Test will be used to assess lower-limb power through video-based analysis of standing-up movements, providing values for time, power, and velocity (pre- and post-protocol).

The Timed Up and Go (TUG) Test will assess balance and fall risk. Participants will stand up from a chair, walk 3 meters, turn around, return, and sit down again. Two repetitions per session will be performed with one-minute rest intervals.

Handgrip strength will be measured (pre- and post-intervention) to assess upper-limb muscle strength.

Isokinetic strength tests will evaluate lower-limb strength (pre- and post-intervention).

Laboratory Tests

Serum analyses will include measurement of interleukin-6,

Blood samples will be collected at four time points:

Pre, during and immediately post-intervention.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis Performance Enhancement Supplemental Nutrition Assistance Program Education Strength Outcomes Function Improvement Intervention Study

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

A randomized parallel study will be conducted in which 100 participants with multiple sclerosis will be divided into four groups: one group will take 2 g of DHA (4 capsules; n = 25), another group will take 2 g of DHA (4 capsules; n = 25) combined with therapeutic exercise, a third group will take placebo (4 capsules; n = 25), and a fourth group will take placebo (4 capsules; n = 25) combined with therapeutic exercise.

All participants will complete the study. The duration of the intervention will be 3 months.

DHA = docosahexaenoic acid. Placebo = sunflower oil.

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

The company that formulated the Omega-3 and placebo carried out the randomization, so no one on the research team or among the sponsors knew which group each study subject belonged to. The results of the randomization were sent to our laboratory after the study was completed to determine which subjects were in each group.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.